Online Suppl. Fig. 1

Nov 06, 2014

10 likes | 158 Vues

4500. CD133+. 4000. CD34+. 3500. VEGFR2+. 3000. 2500. Events. 2000. 1500. 1000. 500. 0. Online Suppl. Fig. 1. A. Tag 4 EBM Whole Gate. Ulex europaeus Lectin Binding. DiI-Ac-LDL Uptake. DAPI. B.

Share Presentation

Embed Code

Link

vegfr2
online suppl
tag 4 ebm
ulex europaeus lectin binding
dii ac ldl uptake

elaine-hart

Télécharger la présentation

Online Suppl. Fig. 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

4500 CD133+ 4000 CD34+ 3500 VEGFR2+ 3000 2500 Events 2000 1500 1000 500 0 Online Suppl. Fig. 1 A Tag 4 EBM Whole Gate Ulex europaeus Lectin Binding DiI-Ac-LDL Uptake DAPI B

(Suppl. Fig . 1)

(Suppl. Fig . 1). primary HCC samples & non-cancerous tissues, from 61 patients (Table 1). RMA normalization Limma (p values) pFDR (q values). Bioconductor packages. Training cohort I (Fig. 1A-B; GSE45267 ). 449. Training cohort II (Fig. 1C; GSE45434 ). 247. 10500. Young HCC

204 views • 1 slides

Suppl. Fig. S1

Suppl. Fig. S1.

197 views • 9 slides

Suppl. Fig . 1

114 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. Day 14. Day 42. Day 7. Day 28. 4. 4. 5. 6. 4. 11. 5. 6. 4. 11. 5. 6. 7. 8. 9. 10. 11. 5. 6. 7. 8. 9. 10. 11. 7. 8. 9. 10. 7. 8. 9. 10. 13. 13. 13. 13. 13. 12. 13. 12. 13. 12. 13. 12. 12. 13. 12. 13. 13. 12. 13. 13. 12. 12.

89 views • 1 slides

Suppl Fig. 1

B/Uganda/MUWRP-064/2009. B/Uganda/MUWRP-068/2009. B/Uganda/MUWRP-055/2009. B/Uganda/MUWRP-081/2009. B/Uganda/MUWRP-073/2009. B/Uganda/MUWRP-054/2009. 87. B/Uganda/MUWRP-063/2009. 100. B/Uganda/MUWRP-077/2009. B/Brisbane/60/2008. B/Fujian- Gulou /1272/2008. B/Florida/4/2006.

177 views • 1 slides

Suppl. Fig.1

No PI. Bax. Suppl. Fig.1. 200. Control. 0%. Ku80. 43.75%. Matsuyama. b. Control. c. 200. Counts. Ku80. 8.78%. Ku70wt. 80. b -Tubulin. M1. Counts. 0. Control. 0.5 m g. 1.0 m g. 2.0 m g. 0. 1. 2. 3. 4. 10. 10. 10. 10. 10. 60. FL2-H. M1. Ku70. 0. 0. 1.

133 views • 4 slides

Suppl. Fig. 2

Suppl. Fig. 2.

137 views • 1 slides

Suppl. Fig. 4

Suppl. Fig. 4.

81 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. Suppl. Fig. 1 Characterisation of three independent iAGP-pea lines. Embryos from independent lines iAGP-1, 2 and 3 were analysed for AGP small subunit-mRNA (A), AGP-activity (B), starch (C), vicilin mRNA (D) and legumin-mRNA (E). Suppl. Fig. 2.

165 views • 3 slides

Suppl. Fig. 2

4. 4. 3. 3. sugar concentration log ng/µl serum or ng/µg. sugar concentration log ng/µl serum or ng/µg. 2. 2. 1. 1. 0. 0. Suppl. Fig. 2. A. B. C. i.p. oral L-arabinose. oral L-rhamnose. 4. Serum. Serum. L-arabinose. Cecum. Cecum. L-rhamnose. SI. SI. 3. LI. LI.

120 views • 1 slides

Suppl. Fig.2

Zou et al. Suppl. Fig.2. A. B. ECM Gel. Cell Culture plate. HA- b -Arr1 1-180. HA- b -Arr1 1-240. HA- b -Arr1 1-320. HA- b -Arr1 181-418. HA- b -Arr1 214-418. HA- b -Arr1 318-418. b -gal. HA- b -Arr1. C. MMP9 Activity. Angiogenesis. +. +. HA- b -Arr1. -. -.

96 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. GL-261 NS. SMA-560 NS. Suppl. Fig. 2. RAD. GL-261. SMA-560. Cil. Merge. Merge. NHS-Biotin. NHS-Biotin. Nucleus. Nucleus. Suppl. Fig. 3. A. B. Suppl. Fig. 4. SMA-560 SC. RAD. Cil. Stauro. Suppl. Fig. 5. GL-261 NS. SMA-560 NS. SMA-560 NS. GL-261 NS.

169 views • 6 slides

Suppl Fig. S1

Suppl Fig. S1. 3 H-thymidine incorporation (cpm). *. *. 100 μ M. Kynurenine concentration. 100 µM. 10 µM. 0 µM. 3HK. 0 µM. 100 µM. 10 µM. 3HAA. Suppl Fig. S2. 25 µM. 0 µM. 50 µM. 100 µM. 3HK. A. 25 µM. 50 µM. 100 µM. 0 µM. 3HAA. B. Suppl Fig. S3. Kyn. 3HK.

151 views • 4 slides

Suppl. Fig. 3

Suppl. Fig. 3. # 2. # 1. A. # 1. B. 42%. AD. # 2. 44%. AD/FasL. # 3. 39%. AD/FasL/ a -Fas. Analysis of BM-MSC adipogenesis.

93 views • 1 slides

Suppl. Fig. 1A

Suppl. Fig. 1A. Suppl. Fig. 1B. Suppl. Fig.1C.

112 views • 2 slides

Suppl. Fig. 1

Suppl. Fig. 1. A. B. P BAD. P rha. 4. 4. 3. 3. Bioluminescence x 10 10 (p/s/cm 2 /sr). Bioluminescence x 10 11 (p/s/cm 2 /sr). 2. 2. 1. 1. 0. 0. 0. 10. 20. 30. 40. 50. 0. 10. 20. 30. 40. 50. Time (h). Time (h).

106 views • 1 slides

Suppl. Fig. 1

Suppl. Fig. 1. A. B. C. 1600. Pre-treatment. vehicle. 10000. vehicle. 24 hr. 1400. 800. Dulanermin 60 mg/kg. Dulanermin 60 mg/kg. 48 hr. 1200. 8000. 600. 1000. 6000. Luminescence (RLU). M30 antigen (U/L). Mean tumor vol (mm 3 ). 800. 400. 600. 4000. 400. 200. 2000.

141 views • 2 slides

Suppl. Fig . S2

Supplementary Figure S1-S2. Suppl. Fig . S2. Suppl. Fig . S1. Cd. Control. Fig. S2B. Fig. S2A. MRP1. MK. Prob. MK. Prob. Cd - + - + - +. Cd - + - + - +. MRP1. p-Ser GSK3 αβ. Procaspase-3. p-Tyr GSK3 αβ. Cleaved caspase-3. Hoechst. GSK3 αβ.

173 views • 4 slides

Suppl. Fig.1

Flag-TDP-43WT. Flag-TDP-12xQ/N. -. -. TET. +. +. 80. 58. 46. 30. a -Flag. a -Tub. Suppl. Fig.1. Flag-TDP-43WT (+ TET). Flag-TDP-12xQ/N (+ TET). a - TDP-43. a -HSP70. MERGE ( a - TDP-43/ a -HSP70. MERGE ( a - TDP-43/ a - Flag /TOPRO-3. Suppl.Fig. 2. Flag- TDP-12xQ/N.

199 views • 6 slides

Suppl. Fig . 1

Suppl. Fig . 1. D. -. -. 0.3. -. -. -. -. 0.3. 0.3. -. -. -. -. Me, M. -. -. -. 0.3. 1. -. -. -. -. 0.3. 0.3. 1. 1. Ea , M. -. -. -. -. -. 0.3. 1. 0.3. 1. 0.3. 1. 0.3. 1. SAHA, M. IKB. Primary PyMT tumor cells.  -tubulin.

98 views • 1 slides

Suppl. Fig. S3

Suppl. Fig. S3.

68 views • 1 slides

Suppl. Material Fig. 1

Suppl. Material Fig. 1.

79 views • 1 slides

More Related